Key Takeaways
- Researchers created a lab-grown esophagus from a pig’s tissue, using muscle progenitor cells from the patient.
- This innovative approach addresses long-gap esophageal atresia (LGEA) in children by providing a functional replacement food pipe.
- The graft shows promising results with no need for immunosuppression, as it uses the patient’s own cells, reducing complications.
- After implantation, the graft developed and functioned like native tissue, achieving key milestones towards clinical application.
- The team aims for human trials within five years, offering hope for families facing complex interventions for esophageal atresia.
A strip of pig tissue, stripped bare of every pig cell, sits in a glass chamber while fluid pulses through it at precisely 6.25 millilitres per minute. Around it, injected in 120 precise punctures, are muscle progenitor cells taken from a biopsy no bigger than a postage stamp. The cells are settling. Spreading. Beginning to feel at home. In roughly eight weeks, this object, unremarkable to look at, pink and tubular and not quite two inches long, will be sewn into a living, growing animal as a replacement food pipe.
What comes next is what researchers at Great Ormond Street Hospital and University College London have been working toward for years. Published today in Nature Biotechnology, their results represent the first time a fully circumferential, lab-grown esophagus has been shown to safely restore function in a growing large-animal model. No immunosuppression. No sacrifice of other organs. Just a scaffold, some cells, and a body that eventually, slowly, makes the new tissue its own.
The target patients are children born with long-gap esophageal atresia (LGEA), a condition in which the food pipe simply isn’t there. Where a continuous tube should connect mouth to stomach, there’s a gap: sometimes several centimetres of missing tissue, detected before birth, confirmed in the delivery room, requiring urgent intervention before feeding can begin. Around 1 in 3,500 newborns have some form of esophageal atresia; roughly ten percent of those have the long-gap variant that makes straightforward repair impossible. In the UK, that’s perhaps eighteen babies a year facing what surgeons describe as one of paediatric medicine’s more stubborn problems.
Current solutions involve repositioning the stomach or sections of bowel to bridge the gap. These are major operations with lasting consequences: breathing difficulties, reflux, dysmotility, and a poorly understood long-term cancer risk. They work, often well, but they come with a cost. Better options have been sorely needed.
The new approach starts with a donor pig’s esophagus, which is structurally close enough to its human counterpart that the comparison is not merely approximate. Through a ten-day decellularisation process, the pig cells are flushed away using detergents and enzymes, leaving the extracellular matrix intact: the collagen scaffolding, the structural proteins, the organ’s physical architecture without any of the immunogenic material that would trigger rejection. The result is, in a sense, a blank esophagus. Then the personalisation begins. Muscle progenitor cells called mesoangioblasts, along with fibroblasts, are taken from a small biopsy of the intended recipient’s own abdominal muscle and fascia, expanded in the lab over six or seven weeks, then microinjected throughout the scaffold. The graft goes into a bioreactor for a week; the cells adapt, shifting toward a proangiogenic state that primes the tissue for the blood vessel ingrowth it will need to survive transplantation.
The esophagus has an unusual blood supply that makes conventional transplantation impractical. Unlike the heart or kidney, it lacks dedicated vessels that surgeons can connect; it is instead fed by small branches from surrounding structures, making it essentially impossible to transplant as an intact organ in the way other solid organs are. This is why bioengineering a replacement, rather than transplanting a donor one, is the more viable path.
Mesoangioblasts are pericyte-like progenitor cells found in muscle tissue that have the ability to differentiate into both smooth muscle and skeletal muscle depending on their local environment. That dual potential is valuable here because the esophagus contains both muscle types and requires them to work in coordination. Crucially, mesoangioblasts have already been shown to be safe in human clinical trials for muscular dystrophy, which simplifies their eventual translational use in children.
The entire process from biopsy to transplant-ready graft takes approximately eight weeks. That window fits comfortably within the typical clinical timeline for managing long-gap esophageal atresia, during which babies are fed via gastrostomy while their care team prepares a treatment plan. In practice, cells could be taken from the biopsy made when the feeding tube is inserted, then the graft prepared in parallel with normal care.
No. Because the graft was populated with the recipient animal’s own cells before implantation, the immune system recognised it as self. The absence of immunosuppression is one of the study’s more significant findings, since the drugs required to prevent rejection carry substantial long-term risks in children, including increased infection susceptibility and malignancy.
The decellularised pig extracellular matrix acts as a temporary framework that the body gradually replaces with its own tissue. Over the six-month study period, the grafts showed progressive remodelling: host cells moved in, new blood vessels formed, muscle regenerated in layers, and neural structures appeared. By six months the grafts were biomechanically and architecturally beginning to resemble native esophageal tissue, though with more fibrosis than in untreated tissue, suggesting remodelling was still ongoing.
“The oesophagus is a really complex organ, without a blood supply from its own vessels, so it cannot be ‘transplanted’ in the way you might expect,” says Professor Paolo De Coppi of UCL’s Great Ormond Street Institute of Child Health, who led the research. The engineering challenge is not merely building tissue that looks right but tissue that actually works, contracting in coordinated waves to move food from throat to stomach. That’s peristalsis, and previous attempts at circumferential esophageal tissue engineering hadn’t managed it. Grafts narrowed, stiffened, lost function. None demonstrated the coordinated muscle contraction that eating actually requires.
The new grafts did. Eight minipigs, each around ten kilograms (chosen deliberately to model the pediatric scale), received transplants of 2.5-centimetre engineered esophageal segments through thoracotomy. All survived the critical first thirty days. By six months, 63% had reached the planned endpoint; asymptomatic, orally fed, growing at normal rates. High-resolution impedance manometry, measuring pressure waves along the length of the esophagus, confirmed secondary peristalsis across the graft in seven animals. Contractility testing on explanted tissue confirmed the muscle was genuinely contracting, not merely present. Spatial transcriptomics, mapping gene expression across the physical cross-section of the graft tissue, showed progressive recapitulation of native esophageal architecture over time: smooth muscle regeneration appeared first, followed by skeletal muscle, then neural structures, echoing the sequence seen in fetal esophageal development. The body, it seems, knows what order to do things in; the graft just needs to be permissive enough to let it.
Morbidities there were. Epithelial polyps formed in all animals in the early postoperative period, managed with steroids and endoscopic resection. Strictures occurred when stents migrated, requiring balloon dilation. Three animals did not reach the six-month endpoint, having reached the maximum number of endoscopic interventions permitted under the study licence. These complications closely mirror what is encountered in current clinical management of esophageal atresia repair, which the team takes as meaningful rather than discouraging; the biology of the problem hasn’t changed, but the solution has become, potentially, reversible.
Dr Natalie Durkin, the study’s lead author and a paediatric surgical registrar at GOSH, points out that the work represents more than a survival figure. “After successful implantation, our grafts grew, matured and began to function like native tissue,” she says. “Each one of these steps represents a key milestone in being able to deliver this as a viable treatment option for children in the near future.” The timeline the team has in mind is perhaps five years to first-in-human trials. There are refinements still needed: longer grafts for adult disease, automated cell injection, cell-tracking approaches compatible with immunocompetent animals, standardised manufacture.
For families already living with the condition, the research represents a different kind of milestone. Silviya, mother of two-year-old Casey McIntyre, who was born missing eleven centimetres of esophagus, described what the prospect of a single, early operation using a ready-built graft would mean for families navigating the current patchwork of interventions: her husband Sean put it more plainly. “The idea that there could be one operation early in your child’s life, that could transplant a working piece of oesophagus, and then we could move on would be life changing.”
De Coppi draws an analogy that puts the ambition in context. Pig heart valves have been used in cardiac surgery for more than fifty years; xenotransplantation, the use of animal tissue in humans, is already part of clinical life. What the GOSH team is proposing is a version of that principle taken further: not just animal tissue, but animal tissue repopulated with the patient’s own cells, individualised, grown, implanted, and left to mature into something the body treats as its own. Whether the same logic can eventually be applied to other hollow organs (the trachea, the bladder, perhaps others) is a question the team is clearly already asking.
DOI / Source: https://doi.org/10.1038/s41587-026-03043-1
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.